SCHEMBL13381802

SCHEMBL13381802

Oc1ccccc1/C=N/Nc1nnn[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 10/20 0.58
▸ GAA P10253 8/20 0.58
▸ KMT2A Q03164 11/20 0.54
▸ MAPT P10636 6/20 0.54
▸ MEN1 O00255 6/20 0.54
▸ HPGD P15428 4/20 0.54
▸ ALDH1A1 P00352 2/20 0.54
▸ GFER P55789 1/20 0.54
▸ JMJD6 Q6NYC1 1/20 0.51
▸ SMN1; SMN2 Q16637 8/20 0.49
▸ LMNA P02545 5/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.49
▸ USP2 O75604 1/20 0.49
▸ CASP6 P55212 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ HTT P42858 4/20 0.48
▸ POLB P06746 2/20 0.48
▸ CTRC Q99895 1/20 0.46
▸ DUSP3 P51452 1/20 0.46
▸ PTPN5 P54829 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11887660 0.81 KMT2A (0.54) KDM4EGAAKMT2AMAPTMEN1
SCHEMBL15558826 0.78 CTH (0.54) KDM4EGAAKMT2AMAPTMEN1
SCHEMBL15558824 0.78 CTH (0.54) KDM4EGAAKMT2AMAPTMEN1
SCHEMBL15549769 0.76 KMT2A (0.60) KDM4EGAAKMT2AMAPTMEN1
SCHEMBL15549000 0.76 CTH (0.56) KDM4EGAAKMT2AMAPTMEN1
SCHEMBL15548998 0.76 CTH (0.56) KDM4EGAAKMT2AMAPTMEN1
SCHEMBL4745948 0.75 GAA (0.41) KDM4EGAAKMT2AMAPTMEN1
SCHEMBL4745944 0.75 GAA (0.41) KDM4EGAAKMT2AMAPTMEN1
SCHEMBL30416505 0.74 CA12 (0.51) KDM4EGAAMAPTHPGDALDH1A1
SCHEMBL28667890 0.73 CA12 (0.50) KDM4EGAAMAPTHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190201414-A1 INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2019-07-04 — — US disclosed
US-8450368-B2 Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy UNIVERSITY OF MARYLAND, BALTIMORE (US) 2013-05-28 — — US disclosed
US-8450368-B2 Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy UNIVERSITY OF MARYLAND, BALTIMORE (US) 2013-05-28 — — US disclosed
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2010-04-01 — — US disclosed
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2010-04-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY HMOX1, HMOX2, PPOX KDM4E 2274/4885GAA 2000/4885KMT2A 3310/4885
US-20190201414-A1 INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION HMOX1, HMOX2, PPOX KDM4E 2238/4885GAA 504/4885KMT2A 3355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback